With CRISPR’s meteoric rise as a gene editing marvel, it’s easy to forget its lowly origins: it was first discovered as a quirk of the bacterial immune system.

CRISPRoff can cause a gene to stay silent for hundreds of generations, even when its host cells morph from stem cells into more mature cells.

This remarkable technology has the potential to eliminate all genetic disorders and is already delivering results that scientists say were unimaginable just a few years ago.

When it comes to Alzheimer’s versus science, science is on the losing side. Alzheimer’s is cruel in the most insidious way. The disorder creeps up in some aging brains, gradually eating away at their ability to think and reason, whittling down its grasp on memories and reality. As the world’s population ages, Alzheimer’s is rearing its ugly head at a shocking rate. And despite decades of research, we have no treatment—not to mention a cure.

A patient suffering from a genetic form of childhood blindness regained and retained vision for more than a year after receiving just a single shot of an experimental RNA therapy directly into the eye, according to a new study published in the journal Nature Medicine.

The future of cancer treatment might involve personalized vaccines meant to manage or even prevent relapses—at least if new research published Thursday continues to pan out. In a small clinical trial, high-risk melanoma patients given such a vaccine were able to create a long term, durable immune response to their cancer, scientists said. They also remained alive four years after the initial treatment, with most being actively disease-free.

Some believe that soon humans will be able to live 1,000 years. We will continue to die, but instead of dying in the hospital while all our organs fail at the age of 90, we could spend a thousand years surrounded by the people we love, enjoying life. The basic idea behind biological aging is that aging occurs as you gradually accumulate damage to various cells and tissues in the body.

The last thing a lot of people want to do these days is get on a plane. But even a pandemic would not stop Victoria Gray. She jumped at the chance to head to the airport this summer. "It was one of those things I was waiting to get a chance to do," says Gray. She had never flown before because she was born with sickle cell disease. She feared the altitude change might trigger one of the worst complications of the devastating genetic disease — a sudden attack of excruciating pain.

It is a double milestone: new evidence that cures are possible for many people born with sickle cell disease and another serious blood disorder, beta-thalassemia, and a first for the genome editor CRISPR.

Researchers at Tel Aviv University (TAU) have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers, a significant step on the way to finding a cure for cancer. The researchers developed a novel lipid nanoparticle-based delivery system that specifically targets cancer cells and destroys them by genetic manipulation. The system, called CRISPR-LNPs, carries a genetic messenger (messenger RNA), which encodes for the CRISPR enzyme Cas9 that acts as molecular scissors that cut the cells' DNA.

The recognized pioneers of controversial gene-editing tool "Crispr-Cas9" are recently awarded by this year's Nobel Prize in Chemistry. Scientists Emmanuelle Charpentier and Jennifer Doudna are two women researchers that are recently added to the list of Nobel Prize winners of the world. This tool has been controversial due to its past issues of allegedly altering the genes of two unborn twins in China to stop them from acquiring AIDS.

CRISPR gene editing can turn white fat cells into brown fat that burns energy, a technique that limited weight gain in mice and could potentially be used to treat obesity-related disorders

A new protein opens doors for gene editing by gaining access to hard-to-reach areas of the genome.

Meet the sturddlefish: a new species of fish accidentally created by scientists in Hungary. It's an unusual mix of two endangered species, the American Paddlefish and the Russian Sturgeon. According to a study published in the journal Genes, researchers at Hungary's National Agricultural Research and Innovation Centre, Research Institute for Fisheries and Aquaculture said that they were not trying to create a new fish when the sturddlefish was born. Rather, they just wanted to know if the two species could be bred in captivity — and were shocked when the resulting fish actually grew to adulthood.

The CRISPR-Cas9 gene editing system is an extremely powerful tool, but there are still a few kinks to iron out. One of the main problems is off-target edits, which can have serious consequences. Now, researchers have found a particular mutation of the CRISPR enzyme that’s almost 100 times more precise than the most commonly used one.

Two people with beta thalassaemia and one with sickle cell disease no longer require blood transfusions, which are normally used to treat severe forms of these inherited diseases, after their bone marrow stem cells were gene-edited with CRISPR.

Many basic and clinical researchers are testing the potential of a simple and efficient gene editing approach to study and correct disease-causing mutations for conditions ranging from blindness to cancer, but the technology is constrained by a requirement that a certain short DNA sequence be present at the gene editing site.

What would the implications be if decoding your genes cost less than a pair of designer jeans? We might soon find out after a Chinese company claimed it can sequence the human genome for $100. The speed at which the price of genetic sequencing has fallen has been astonishing, from $50,000 a decade ago to roughly $600 today. For a long time, the industry saw the $1,000 genome as the inflection point at which we would enter the genomic age—where getting a read out of your DNA would be within reach for huge swathes of the population.

The tool was used in an attempt to treat a patient's blindness. It may take up to a month to see if it worked.

The gene-editing tool CRISPR has been used for the first time inside the body of an adult patient, in an attempt to cure a form of blindness. The treatment: According to the Associated Press, doctors dripped just a few drops of a gene-editing mixture beneath the retina of a patient in Oregon who suffers from Leber congenital amaurosis, a rare inherited disease that leads to progressive vision loss.